JP7211961B2 - 酸性ｐＨでＶＩＳＴＡに結合する抗体 - Google Patents

酸性ｐＨでＶＩＳＴＡに結合する抗体 Download PDF

Info

Publication number
JP7211961B2
JP7211961B2 JP2019549389A JP2019549389A JP7211961B2 JP 7211961 B2 JP7211961 B2 JP 7211961B2 JP 2019549389 A JP2019549389 A JP 2019549389A JP 2019549389 A JP2019549389 A JP 2019549389A JP 7211961 B2 JP7211961 B2 JP 7211961B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
light chain
seq
e100ff
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509756A5 (enExample
JP2020509756A (ja
Inventor
ロバート ジェー． ジョンストン，
アルビンド ラジパール，
ポール オー． シェパード，
ルイス ボルヘス，
アンドリュー ランキン，
キース サアドゥン バハジャト，
アラン ジェー． コーマン，
アンディ エックス． トン，
リン ホイ スー，
ジンジャー レイクストロー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020509756A publication Critical patent/JP2020509756A/ja
Publication of JP2020509756A5 publication Critical patent/JP2020509756A5/ja
Priority to JP2023002879A priority Critical patent/JP7573659B2/ja
Application granted granted Critical
Publication of JP7211961B2 publication Critical patent/JP7211961B2/ja
Priority to JP2024179648A priority patent/JP2025023919A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019549389A 2017-03-14 2018-03-13 酸性ｐＨでＶＩＳＴＡに結合する抗体 Active JP7211961B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023002879A JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2024179648A JP2025023919A (ja) 2017-03-14 2024-10-15 酸性ｐＨでＶＩＳＴＡに結合する抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471196P 2017-03-14 2017-03-14
US62/471,196 2017-03-14
US201862636746P 2018-02-28 2018-02-28
US62/636,746 2018-02-28
PCT/US2018/022230 WO2018169993A1 (en) 2017-03-14 2018-03-13 Antibodies binding to vista at acidic ph

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023002879A Division JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体

Publications (3)

Publication Number Publication Date
JP2020509756A JP2020509756A (ja) 2020-04-02
JP2020509756A5 JP2020509756A5 (enExample) 2021-04-30
JP7211961B2 true JP7211961B2 (ja) 2023-01-24

Family

ID=63522565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549389A Active JP7211961B2 (ja) 2017-03-14 2018-03-13 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2023002879A Active JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2024179648A Pending JP2025023919A (ja) 2017-03-14 2024-10-15 酸性ｐＨでＶＩＳＴＡに結合する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023002879A Active JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2024179648A Pending JP2025023919A (ja) 2017-03-14 2024-10-15 酸性ｐＨでＶＩＳＴＡに結合する抗体

Country Status (18)

Country Link
US (3) US11603406B2 (enExample)
EP (1) EP3595720A4 (enExample)
JP (3) JP7211961B2 (enExample)
KR (2) KR20240151866A (enExample)
CN (2) CN118894937A (enExample)
AU (2) AU2018236218B2 (enExample)
BR (1) BR112019019108A2 (enExample)
CA (1) CA3054067A1 (enExample)
CL (2) CL2019002610A1 (enExample)
CO (1) CO2019010943A2 (enExample)
IL (1) IL269240A (enExample)
MX (1) MX2024003316A (enExample)
MY (1) MY200609A (enExample)
PE (2) PE20250933A1 (enExample)
SG (1) SG11201907848YA (enExample)
TW (2) TWI890190B (enExample)
WO (1) WO2018169993A1 (enExample)
ZA (1) ZA201905525B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
DK2970473T3 (da) * 2013-03-14 2017-11-27 Bristol Myers Squibb Co Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018132476A1 (en) 2017-01-11 2018-07-19 Bristol-Myers Squibb Company Psgl-1 antagonists and uses thereof
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
KR20240151866A (ko) 2017-03-14 2024-10-18 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
ES2923143T3 (es) 2017-05-25 2022-09-23 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra CD40 y sus usos
JP7510879B2 (ja) 2018-03-21 2024-07-04 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
KR20210031722A (ko) * 2018-07-11 2021-03-22 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
MX2021000786A (es) * 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP7650867B2 (ja) * 2019-09-19 2025-03-25 ブリストル－マイヤーズ スクイブ カンパニー 酸性ｐＨでＶＩＳＴＡと結合する抗体
PE20221661A1 (es) 2019-12-18 2022-10-26 Hoffmann La Roche Anticuerpos anti-ccl2 biespecificos
WO2023001987A2 (en) 2021-07-22 2023-01-26 University Of Dundee Therapeutic muteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5605821A (en) 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
JP3096305B2 (ja) 1990-07-17 2000-10-10 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ Ｇｍｐ―１４０に対する糖タンパク質リガンド
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
DK0666914T3 (da) 1992-10-23 2004-04-13 Inst Genetics Llc Hidtil ukendt P-selectin-ligandprotein
AU681369B2 (en) 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
AU2361395A (en) 1994-04-28 1995-11-29 Genetics Institute Inc. Novel P-selectin ligand protein
JPH11510543A (ja) 1995-08-03 1999-09-14 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ ペプチド及びセレクチン介在炎症のｏ−グリカン阻害剤
AU716154B2 (en) 1995-09-01 2000-02-17 University Of Washington Interactive molecular conjugates
JP2002508167A (ja) 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003504056A (ja) 1999-07-08 2003-02-04 財団法人相模中央化学研究所 疎水性ドメインを持つヒト蛋白質とそれをコードするｄｎａ
WO2001073028A2 (en) 2000-03-24 2001-10-04 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
CN102617708B (zh) 2004-05-11 2016-05-18 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
US7919585B2 (en) 2004-06-24 2011-04-05 Mayo Foundation For Medical Education And Research B7-H5, a costimulatory polypeptide
US8236304B2 (en) 2005-04-25 2012-08-07 Trustees Of Dartmouth College Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity
US8231872B2 (en) 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
US7655778B2 (en) 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
US20100129368A9 (en) 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
CA2694396A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binding agents directed to kdr and uses thereof - 035
EP2240203B1 (en) 2008-02-05 2014-04-09 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
JP2011524858A (ja) 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
KR101979188B1 (ko) * 2009-03-09 2019-05-16 바이오아트라, 엘엘씨 미락 단백질
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
MX342017B (es) * 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
JP6240611B2 (ja) * 2011-10-28 2017-11-29 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
CA2857019C (en) 2011-11-28 2022-08-16 Gray D. Shaw Soluble tandem selectin glycoprotein ligand molecules
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
HUE043903T2 (hu) 2012-12-03 2019-09-30 Bristol Myers Squibb Co Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
EP4461372A3 (en) 2013-11-05 2025-01-22 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US10273301B2 (en) * 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
CA2936926C (en) 2014-01-14 2023-08-29 Mark Spaller Vista antagonist and methods of use
RU2550262C1 (ru) 2014-02-28 2015-05-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
WO2015187359A1 (en) 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
WO2016007653A2 (en) 2014-07-08 2016-01-14 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
JOP20150008B1 (ar) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv أجسام مضادة ل vista وأجزاء منها
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
HUE061253T2 (hu) * 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
MX395252B (es) 2016-01-08 2025-03-25 Altrubio Inc Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos.
MX2018009800A (es) * 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
WO2018132476A1 (en) 2017-01-11 2018-07-19 Bristol-Myers Squibb Company Psgl-1 antagonists and uses thereof
KR20240151866A (ko) 2017-03-14 2024-10-18 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
WO2018195772A1 (en) 2017-04-25 2018-11-01 Sun Yat-Sen University Pd-1h as target in treatement of asthma
JP2020525005A (ja) 2017-06-22 2020-08-27 アペクシジェン， インコーポレイテッド 抗ｖｉｓｔａ抗体および使用方法
CN111465617B (zh) 2017-10-20 2023-08-25 药物抗体公司 抗vista抗体及其用途
JP7378395B2 (ja) 2017-11-06 2023-11-13 オーリジーン オンコロジー リミテッド 免疫調節のためのコンジョイントセラピー
CN112040959A (zh) 2018-02-23 2020-12-04 真和制药有限公司 通过阻断vista和其结合伴侣的相互作用治疗癌症
JP7510879B2 (ja) * 2018-03-21 2024-07-04 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
WO2019185163A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Vista antigen-binding molecules
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
KR20210031722A (ko) 2018-07-11 2021-03-22 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
CN109878421B (zh) 2019-03-13 2020-11-03 浙江吉利控股集团有限公司 车辆坡道装置及汽车
CN110563843A (zh) 2019-07-25 2019-12-13 钟小泉 一种靶向人vista蛋白的单克隆抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal for ImmunoTherapy of Cancer, 2016, Vol.4, No.86, pp.1-7

Also Published As

Publication number Publication date
AU2018236218A1 (en) 2019-09-12
MY200609A (en) 2024-01-05
IL269240A (en) 2019-11-28
CL2019002610A1 (es) 2019-11-29
SG11201907848YA (en) 2019-09-27
TW201843171A (zh) 2018-12-16
CN110740749B (zh) 2024-12-10
US11603406B2 (en) 2023-03-14
AU2018236218B2 (en) 2025-03-06
TW202423986A (zh) 2024-06-16
ZA201905525B (en) 2024-12-18
US20200055936A1 (en) 2020-02-20
TWI825010B (zh) 2023-12-11
KR102715540B1 (ko) 2024-10-08
AU2025203967A1 (en) 2025-07-03
EP3595720A1 (en) 2020-01-22
US20250206822A1 (en) 2025-06-26
PE20191708A1 (es) 2019-11-28
PE20250933A1 (es) 2025-04-02
JP2025023919A (ja) 2025-02-19
BR112019019108A2 (pt) 2020-04-22
KR20240151866A (ko) 2024-10-18
CL2021002769A1 (es) 2022-08-12
US12195535B2 (en) 2025-01-14
TWI890190B (zh) 2025-07-11
WO2018169993A1 (en) 2018-09-20
US20240092907A1 (en) 2024-03-21
MX2024003316A (es) 2024-04-04
JP7573659B2 (ja) 2024-10-25
CN110740749A (zh) 2020-01-31
CO2019010943A2 (es) 2020-01-17
KR20190128198A (ko) 2019-11-15
JP2020509756A (ja) 2020-04-02
CA3054067A1 (en) 2018-09-20
EP3595720A4 (en) 2021-05-26
JP2023061927A (ja) 2023-05-02
CN118894937A (zh) 2024-11-05

Similar Documents

Publication Publication Date Title
JP7573659B2 (ja) 酸性ｐＨでＶＩＳＴＡに結合する抗体
US20250129166A1 (en) Antibodies Binding to Vista at Acidic pH
JP7700036B2 (ja) 酸性ｐＨでＶＩＳＴＡと結合する抗体
JP7650867B2 (ja) 酸性ｐＨでＶＩＳＴＡと結合する抗体
EA042790B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH
EA046477B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230112

R150 Certificate of patent or registration of utility model

Ref document number: 7211961

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150